| Gene symbol | S | Synonyms | E2 | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_004718.3 (21492..25259) | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | spike glycoprotein | ||||
| GTO ID | GTC3209 |
| Trial ID | NCT05580159 |
| Disease | COVID-19 |
| Altered gene | S |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | SW-BIC-213 |
| Phase | Phase3 |
| Recruitment status | Recruiting |
| Title | A Multi-national, Randomized, Observer-blinded, Parallel Controlled Trial to Evaluate the Immunogenicity and Safety of New Generation COVID-19 mRNA Booster Vaccination Against Emerging Variants of Concern (VOC) |
| Year | 2022 |
| Country | Lao People's Democratic Republic |
| Company sponsor | Stemirna Therapeutics |
| Other ID(s) | SWC310 |
| Vector information | |||
|
|||
| Cohort1: SW-BIC-213 | |||||||
|
|||||||
| Cohort2: SARS-Cov-2 Vaccina(Vero Cell) Inactivated | |||||||
|
|||||||